From Purity to Functionality: A Comprehensive Guide to Recombinant Antibody Quality Control Standards

Have you ever encountered situations where Western blot bands were poorly resolved, flow cytometry results were ambiguous, or ELISA data showed poor reproducibility? In such cases, the culprit is very likely to be the antibody you are using. So, how can you evaluate the quality of a recombinant antibody? Today, we will systematically review the common quality control standards for recombinant antibodies that you must know.

图片1.png

Why is quality control (QC) for recombinant antibodies so critical?

Recombinant antibodies are produced by transfecting plasmids encoding antibody genes into specific host cells for expression and production; they offer significant advantages, such as high inter-batch consistency and ease of genetic engineering modification.

However, the drawback is that any deviation in the production process may lead to functional defects in the final product. Therefore, a rigorous and comprehensive QC system is essential.

An excellent recombinant antibody typically must meet rigorous criteria across the following dimensions.

1. fineness

This is the most fundamental requirement: the proportion of the target antibody within the total protein.

Detection method: SDS-PAGE is the most straightforward approach. Under non-reducing conditions, a single main band (intact IgG, approximately 150 kDa) should be observed; under reducing conditions, two distinct bands (heavy chain, approximately 50 kDa; light chain, approximately 25 kDa) should be visible. For more precise quantification, high-performance liquid chromatography (HPLC) or capillary electrophoresis (CE-SDS) can be employed.

Standard: Typically requires>90%; for high-sensitivity applications or clinical use cases, a requirement of>95% or even higher is required.

2. Concentration & Total Amount

Ensure that sufficient quantities of the product are obtained, and that accurate dilutions can be performed during experiments.

Detection method: The ultraviolet spectrophotometry method (at A???) is the most commonly used approach, which calculates the protein concentration based on the absorbance of tyrosine and tryptophan residues within the protein. The BCA method or the Bradford method are also common alternative options.

3. Integrity & Molecular Weight

This step is used to confirm that the antibody obtained has the correct structure and a molecular weight consistent with expectations.

test method ：

SEC-HPLC (Size-exclusion chromatography): This technique is used to analyze the polymerization state of antibodies in their native form.

Mass spectrometry (MS): MS can accurately determine the molecular weight of antibodies, verify whether their amino acid sequences are correct, and also be used to detect the presence of unexpected modifications (such as glycosylation, oxidation, etc.).

4. specificity

This is the core of antibody function! It ensures that the antibody can—and will—bind exclusively to its designed target.

test method ：

ELISA/Blot: Validation performed using recombinant target protein.

Immunofluorescence/Immunohistochemistry: Used to verify whether its localization is correct at the cellular or tissue level.

Flow cytometry: validates whether it can recognize natural targets on the cell surface.

Knockout/Knockdown validation: This serves as the "gold standard" for validating specificity. In cell lines or tissues utilizing gene knockout (KO) or RNAi knockdown (KD), the antibody signal should be significantly attenuated or completely abolished.

5. affinity

The strength and stability of antibody–target binding are typically quantified using the dissociation constant (KD); a lower KD value indicates higher affinity.

Detection methods: Surface Plasmon Resonance (SPR) and Biolayer Interference (BLI) are the gold standards for measuring affinity, as they can provide kinetic parameters (Kon, Koff) and the equilibrium dissociation constant (KD). For therapeutic antibodies, ultra-high affinity at the nM or even pM level is typically required; however, for most research applications, an affinity in the nM range is generally sufficient.

6. functionality

This represents the final "field validation" step, designed to verify whether the antibody functions correctly in specific applications.

test method ：

Neutralizing antibodies: Their ability to block pathogen infection or signal pathway activation must be validated using cell-based models.

Antibody testing: This involves validating the sensitivity and dynamic range of the antibody on the corresponding detection platform (e.g., ELISA, flow cytometry, WB).

Coupled antibodies: primarily used to verify whether the conjugated markers (such as fluorescent dyes, enzymes, or biotin) remain active.

An ideal recombinant antibody should possess the following characteristics: high purity (with clean SDS-PAGE bands), high monomer content (with a distinct main peak in SEC-HPLC analysis), strong specificity (supported by KO/KD validation data), moderate affinity (with a clearly defined KD value), and validated functionality (with a clearly defined KD value).

Tek Biotech(Tianjin) Co., Ltd. has established a comprehensive mammalian cell-based recombinant antibody expression platform dedicated to providing high-quality recombinant antibody expression services for scientists worldwide. Leveraging the advantages of mammalian cell expression systems, this platform ensures the delivery of high-quality recombinant antibodies with high biological activity. We provide robust support for our clients' research projects and the development of novel antibody-based therapeutics.

References

[1] Ha TK,Kim D,Kim CL, [1] Ha TK,Kim D,Kim CL, et al. Factors affecting the quality of therapeutic proteins in recombinant Chinese hamster ovary cell culture. Biotechnol Adv. 2022;54:107831.

[2] Broer LN,Knapen DG,de Groot DA, [2] Broer LN,Knapen DG,de Groot DA, et al. Monoclonal antibody biosimilars for cancer treatment. iScience. 2024;27 (6):110115.

[3] Zhu J.[3] Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv. 2012;30 (5):1158-70.

Previous:How much do you know about the molecular design and mechanism of action of ADC drugs? Next:None!